Elanco

We brought the best of Elanco to our favorite people for Family Day at our Indianapolis HQ! It was a day centered on what matters most: connection. From pickleball games to meeting new furry friends, the energy was unmatched. We're proud to celebrate our Healthy Purpose alongside the people who support us every day.

Today we announced the on-time completion of a 25,000-square-foot expansion at our Elwood, Kansas site as part of a broader $150 million total investment through 2028 – strengthening Elanco's leadership in the biologics space as one of only two animal health companies with mAb solutions on the market today. This facility is more than an infrastructure update; it supports the delivery of our next generation portfolio. As pet owners' expectations for care reach new heights, the demand for innovation increases. This prioritization reflects a growing demand for comprehensive portfolios and innovative solutions, such as monoclonal antibodies, that can enhance the quality of life for pets. Learn more about how we are scaling our global manufacturing capabilities: https://bit.ly/4zElU0C

For food companies, Scope 3 ambition is only as valuable as your ability to turn it into credible, measurable action across the supply chain. At Elanco, we’re helping food companies do exactly that—combining animal health innovation, on-farm expertise, advanced analytics and carbon accounting capabilities to turn sustainability goals into credible outcomes from farm to food company. Meredith Varie recently shared our approach and latest capabilities at the Carbon Accounting in Agricultural Supply Chains Summit in Chicago, joining food and agriculture leaders to tackle a critical question: How do we operationalize evolving carbon accounting standards across beef and dairy supply chains—and translate them into meaningful Scope 3 progress? Our perspective is clear: 🔹Start with the claim. Programs should be designed around the outcomes partners need to credibly measure and report. 🔹Keep farmers at the center. Lasting progress depends on programs that work on the farm, support producer livelihoods and create a positive experience. 🔹Build for rigor and scale. Strong data, verification and implementation capabilities are essential to moving from sustainability ambition to measurable impact. What makes Elanco different? 🔹People. Experienced sustainability and animal agriculture experts with the field presence to support programs from farm identification through implementation and verification. 🔹Programs. Four distinct supply-chain emissions reduction and intensity programs—now independently validated and verified—designed to deliver high-quality outcomes while adapting to partners’ specific claiming needs. 🔹Primary data. UpLook™ and Benchmark provide robust farm-level data collection, quantification and insights, supported by IPCC-aligned methodologies and the latest scientific research. For CPG and food companies looking to make credible progress against Scope 3 targets, the opportunity isn’t simply to measure emissions—it’s to build programs that can reduce them. We’re partnering across the beef and dairy value chains to create end-to-end solutions that connect farm-level action with transparent, credible and claimable outcomes. Interested in what this could look like in your supply chain? Let’s talk. #CarbonAccounting #Scope3 #SustainabilityReporting #AgRetail #CPG #GHGP #Decarbonization

The Riverside Department of Animal Services recently reached a milestone that represents a paradigm shift in shelter medicine. By implementing Trutect™ (formerly Canine Parvovirus Monoclonal Antibody)—the first and only USDA-approved treatment for Canine Parvovirus—they have successfully achieved a 63% reduction in Parvo-related euthanasia rates year-to-date. This dramatic shift is the direct result of what happens when visionary leadership meets first-of-its-kind innovation. For decades, Parvo was a devastating diagnosis for shelters; today, Trutect™ provides the tool veterinarians need to fight back and win. At Elanco, this progress is the living embodiment of our mission: making life better for animals, makes life better. By providing the science to turn a diagnosis of parvovirus into a story of recovery, we are not just advancing veterinary medicine—we are strengthening the essential bond between pets and the communities that care for them.

The re-emergence of New World screwworm (NWS) in the United States represents a significant shift in the parasitic landscape. By collaborating closely with the FDA, EPA and USDA, Elanco has secured more Emergency Use Authorizations and conditional approvals for NWS than any other animal health company. Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) is the first and only FDA-conditionally approved treatment for NWS larvae infestations in dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or greater. This milestone demonstrates our "Healthy Purpose" in action—ensuring that veterinarians and pet owners have the tools they need to be prepared. Read the full article from Dr. Casey Locklear, DVM, veterinarian and leading parasiticides expert at Elanco, on managing this emerging threat here: https://bit.ly/4ct3F4s View the full Credelio Quattro/Credelio Quattro-CA1 product label at CredelioQuattroLabel.com.

If hunger were a country, it would be the third largest in the world. Addressing a crisis of this scale requires more than incremental change. It requires massive action. In the latest episode of Shared Table, Elanco CEO Jeff Simmons and Tony Robbins discuss their fight against hunger: The Coalition to Close the Protein Gap. But this conversation goes beyond logistics; it is a masterclass in the leadership mindset required to turn “impossible” goals into reality. From the “Protein Revolution” to the philosophy of creating the future rather than managing circumstances, this Shared Table conversation explores how a personal “why” can become a global “how.” Watch the full episode here: https://lnkd.in/eCtc2HEt

With the confirmed reentry of New World screwworm into the United States, prevention is key. Elanco is committed to supporting the animal health industry. Today, we secured an Emergency Use Authorization from the U.S. Food and Drug Administration for another preventative solution. By providing livestock producers and veterinarians with the means for early intervention, we are reaffirming our dedication to protecting animal health and producers' livelihoods. Read the full press release: https://bit.ly/4wFMh4w

Our 2026 first half results are in and Elanco is delivering. We exceeded our expectations across our metrics, allowing us to raise our full-year guidance to 6-7% organic constant currency growth. Key highlights from the standout second quarter: 🔹 High-Quality Growth – We achieved 10% reported growth (8% organic constant currency), with strong momentum. Performance was led by a standout 11% growth in both US Pet Health and US Farm Animal, proving the durability of our diverse portfolio. International pet health closely followed with 9% organic constant currency growth. 🔹 Innovation Momentum – Innovation is our engine. Our "Big 6", led by Zenrelia and Quattro, helped drive $340 million of second-quarter revenue from innovation. Zenrelia officially became our newest blockbuster reaching $100 million in revenue YTD in July. We have a significant runway ahead for our basket of innovation, raising our innovation target to $1.25 billion. 🔹 Deleveraging Progress – We continue to pay down debt faster than planned and strengthen our balance sheet, enabling greater capital allocation flexibility. We’ve taken a half-turn out of debt in the first half, moving from 3.6x to 3.1x net leverage in Q2, approaching the under 3.0x landmark. The Big Picture: The animal health industry remains incredibly durable. With pet care as a protected budget item for consumers and animal protein demand at an all-time high, Elanco is positioned to lead through our differentiated innovation, omnichannel go-to-market approach. Congratulations to Global Elanco for your disciplined, relentless execution. Well done on a strong first half! Read the full report here: https://bit.ly/4hf9PbF #WeAreElanco #GoBeyond

On National Assistance Dog Day, we recognize the extraordinary discipline and intuition required of service animals. At Elanco, we believe that same spirit of excellence should extend to our own environment. Through our long-standing partnership with Medical Mutts, we have brought a new level of rigor to our Pets at Work program, ensuring that every canine in our office meets the highest standards of behavior and safety. Medical Mutts Service Dogs provides the expert evaluation necessary to maintain a productive, inclusive and safe workspace for all our employees. This collaboration is more than a program; it is a reflection of our mission to strengthen the human-animal bond while maintaining the professional integrity of our global headquarters.

Today we released our 2025 Impact Report, detailing how Elanco is leading the animal health industry by addressing two of society's most important needs: 1. Nutrition Security: Meeting the rising global demand for protein by helping farmers produce safe, affordable protein more efficiently while protecting our planet’s resources. 2. Human-Animal Bond: Addressing critical health needs through innovation and increasing access to products and services that improve animal well-being—because making life better for animals makes life better. With the animal health industry projected to grow to $60B, Elanco is uniquely positioned to lead with purpose for animals, customers and society. Read the full report and see how we're shaping the future: https://bit.ly/4g28O5C